$ENHA +20.08% today. It's great to finally see the stock moving higher. The last few weeks haven't been easy to hold, but that's the nature of high-risk, high-reward small caps. You have to be prepared for sharp moves in both directions. I'm happy with today's move, but I'm much more interested in next week's FDA Pharmacy Compounding Advisory Committee meeting. The committee will review seven peptides over two days, including BPC-157, TB-500, MOTS-C, KPV, Semax, Epitalon and DSIP. While the recommendations are non-binding, the meeting will be an important catalyst for ENHA.
View on X ↗